research use only
Cat.No.S8911
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other MPS1 Inhibitors | AZ 3146 BAY 1217389 MPI-0479605 Empesertib (BAY1161909) Mps1-IN-6 (Compound 9) CC-671 |
|
In vitro |
DMSO
: 89 mg/mL
(199.3 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 446.55 | Formula | C24H30N8O |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1578245-44-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCOC1=C(C=CC(=C1)C2=NN=CN2C)NC3=NC=C4C=C(N=C(C4=N3)NCC(C)(C)C)C | ||
| Targets/IC50/Ki |
MPS1
(Cell-free assay) 0.11 nM(Ki)
MPS1
(Cell-free assay) 11 nM
|
|---|---|
| In vitro |
This compound optimizes HLM stability, CDK2 selectivity, cellular potency, and solubility. It is potential for the treatment of various forms of breast cancer. |
| In vivo |
BOS172722 shows excellent PK in mouse, rat, and dog. At 1 mg/kg iv and 5 mg/kg po, this compound shows complete bioavailability (100%), low clearance (1.2 mL/min/kg), a moderate volume of distribution (1.1 L/kg), and a 12 h half-life in a dog PK study. The 50 mg/kg dose of this chemical results in an increased suppression of MPS1 autophosphorylation at 6 and 24 h. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03328494 | Completed | Advanced Nonhaematologic Malignancies |
Boston Pharmaceuticals |
October 13 2017 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.